Enterome
Belichard Pierre has a diverse work experience spanning over multiple years. Starting in 1997, they worked as the Associate Director of Business Development at Fournier until 2000. From there, they became the Business Development Director for Europe at Ethypharm until 2002. Moving on, they held the position of VP Business Development at UROGENE from 2002 to 2004. In 2005, they served as the Manager in Residence at SOFINNOVA Partners for a short period before founding Fovea Pharmaceuticals where they worked as the COO until 2009. Subsequently, they joined sanofi-aventis as the VP of Business Development in the Ophthalmology sector until 2011. Finally, they took on the position of CEO at Enterome in 2011.
Belichard Pierre's education history begins in 1981 when they enrolled at Université Joseph Fourier (Grenoble I) and earned a Pharm D degree in Pharmacy. Belichard then pursued further education and completed their PhD in Biology at Pierre and Marie Curie University from 1986 to 1988. Continuing their academic journey, Belichard went on to complete a Post Doc in Pharmacology at Université de Montréal from 1989 to 1990.
Enterome
Enterome’s OncoMimic technology allows the overcoming of immune tolerance against cancer cells, with broad applicability against solid tumor via an off-the-shelf, easy to manufacture technology. Enterome’s potentially first-in-class small protein and peptide drug candidates modulate the immune system by closely mimicking the structure, effect oractions of Tumor Associated Antigens to induce a potent, endogenous CD8 T cell response. The company’s most advanced programs are in Phase 2 clinical trials in hard-to-treat tumors such as glioblastoma, adrenal malignancies and colorectal cancer.